Hospital
ST. Luke's Hospital-Carbon Campus
ST. Luke's Hospital-Carbon Campus was paid $1.36M by Medicaid between Nov 2021 and Nov 2024, across 40 billing codes. Its largest line is 99284, emergency room visit (serious) — 38% of everything it billed.
33Billing provider infoST. LUKE'S HOSPITAL-CARBON CAMPUS
LEHIGHTON, PA 18235
LEHIGHTON, PA 18235
33aNPI1699340927assigned 05/20/2021
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.36M
24GClaims32,022
24DCodes billed40
24AFirst – last monthNov 2021 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#100 of 154
Median peer was paid$2.82M
This provider vs. median0.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WOLFE, SCOTT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 558 | $25K | |
| 2022 | 11,194 | $508K | |
| 2023 | 12,395 | $499K | |
| 2024incomplete | 7,875 | $333K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 38% | 4,264 | 4,154 | $515K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 4,729 | 4,661 | $408K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 1,399 | 1,364 | $248K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 4.3% | 521 | 505 | $59K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 5,173 | 5,025 | $29K |
| 80053 | Comprehensive metabolic panel | 2.1% | 2,972 | 2,869 | $29K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 1,756 | 1,674 | $22K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 583 | 553 | $22K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 37 | 37 | $16K |
| 71045 | Radiologic examination, chest; single view | <1% | 860 | 842 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 38 | 37 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 192 | 190 | $2K |
28 more codes
| 83690 | <1% | 276 | $2K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 28 | $1K |
| 83735 | <1% | 84 | $700.63 | |
| 85610 | <1% | 149 | $487.10 | |
| 80050 | General health panel | <1% | 12 | $462.60 |
| 85730 | <1% | 71 | $383.53 | |
| 84484 | <1% | 12 | $116.85 | |
| 81001 | <1% | 28 | $69.70 | |
| 81003 | <1% | 13 | $32.68 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 597 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 918 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 949 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 416 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 174 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 2,420 | $0.00 |
| J3490 | Unclassified drugs | 0% | 48 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 151 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 267 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 190 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 42 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 606 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 1,471 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 172 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 267 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 61 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 27 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 19 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOLFE, SCOTT (SENIOR VP EXEC ADMIN)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.